Brief: Lisata Therapeutics And Warpnine Announce First Patient Treated In The Ilsta Trial Of Lsta1
18/04/2023 13:30
April 18 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS AND WARPNINE ANNOUNCE FIRST PATIENT
TREATED
IN THE ILSTA TRIAL OF LSTA1, A NOVEL TUMOR-TARGETING AND
PENETRATING PEPTIDE, IN PATIENTS WITH LOCALLY ADVANCED
NON-RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
* LISATA THERAPEUTICS INC - WARPNINE TO PROVIDE FUNDING AND
LOCAL
TRIAL MANAGEMENT
Source text for Eikon: ID:nGNX1CqqDS
Further company coverage: LSTA.O
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal